SALT LAKE CITY - LifeVantage Corporation (NASDAQ:LFVN), a $271 million market cap player in the health and wellness sector with impressive 79% gross profit margins, today announced the successful ...

There's a growing body of evidence that gold nanoparticles can offer significant, targeted weight loss that focuses on fat ...

The discovery, of course, goes beyond those taking GLP-1 medications. And while the BCL6 discovery came through a study on mice, researchers are confident it will translate to human physiology.

The incretin effect is impaired in patients with Type 2 diabetes. Exogenous administration of GLP-1 stimulates insulin secretion, inhibits glucagon secretion, slows gastric emptying, decreases ...

12-week chronic study GLP-1-H24-4 (the "Study") underway in Australia. Lexaria has completed its submission to the human research ethics committee ("HREC") for its planned addition of Study Arm 5 ...

Lexaria Bioscience (LEXX) provided progress updates on its Phase 1b, 12-week chronic study GLP-1-H24-4 underway in Australia. Lexaria has completed its submission to the human research ethics ...

Researchers are keen to explore the possibility, as suggested by the relationship between these medications and improved mental health, that GLP-1 drugs lessen stress responses in human beings.